Compliance with study medication was good in both treatment groups. At visit 3, compliance with placebo was 95.42±4.23% in the indapamide group and 99.33±4.51% in the HCTZ group; compliance was above 95% in both groups at all visits, and at the end of the study compliance was 98.85±6.12% in the indapamide group and 97.12±5.69% in the HCTZ group. buy asthma inhalers
ENROLMENT, ADVERSE EFFECTS, EXCLUSIONS AND DROPOUTS
Forty-four patients were enrolled and randomly assigned to treatment. The age ranged from 27 to 75 years; only five subjects were below age 40 years and the mean age was 54.95±11.6 years. Five patients were excluded from analysis; three from the indapamide and two from the HCTZ group. Results are presented for the 39 patients who completed the study. The two HCTZ exclusions were the result of repeated failure to show up for appointments. Of the indapamide exclusions, one was because of repeated missed appointments and two had adverse effects leading to withdrawal from the study. One man had lower abdominal pain with tenesmus that may have been related to prostatism aggravated by increased diuresis and the other had gout in both feet. A third indapamide subject experienced severe depression that appeared to improve after cessation of medication at the end of the study, but the patient was not removed from the study because the likelihood of a causal relationship appeared to be low.